Behavioural disorders, disability and quality of life in Parkinson's disease
Iracema Leroi(Trinity College Dublin), Alistair Burns(University of Manchester), E. Jane Byrne(University of Manchester), David Ahearn(Wythenshawe Hospital), Michelle Andrews(Emory University), Kathryn McDonald(Salford Royal NHS Foundation Trust)
Cited by 108
Related Papers
Donepezil and Memantine for Moderate-to-Severe Alzheimer's Disease
|New England Journal of Medicine|2012|774
Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial
|The Lancet Neurology|2009|460
Cognitive Impairment in Parkinson Disease
|Journal of Geriatric Psychiatry and Neurology|2012|380
Consumer Connectivity in a Complex, Technology-enabled, and Mobile-oriented World with Smart Products
|Journal of Interactive Marketing|2017|257
Randomized placebo‐controlled trial of donepezil in cognitive impairment in Parkinson's disease
|International Journal of Geriatric Psychiatry|2004|228